JP2012525124A5 - - Google Patents

Info

Publication number

JP2012525124A5

JP2012525124A5 JP2012507644A JP2012507644A JP2012525124A5 JP 2012525124 A5 JP2012525124 A5 JP 2012525124A5 JP 2012507644 A JP2012507644 A JP 2012507644A JP 2012507644 A JP2012507644 A JP 2012507644A JP 2012525124 A5 JP2012525124 A5 JP 2012525124A5

Authority

JP

Japan

Prior art keywords

absent

nucleic acid

nucleotides

nucleotide sequence

stretch

Prior art date

2010-04-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002773 nucleotide Substances 0.000 claims 132
• 125000003729 nucleotide group Chemical group 0.000 claims 131
• 150000007523 nucleic acids Chemical class 0.000 claims 67
• 102000039446 nucleic acids Human genes 0.000 claims 63
• 108020004707 nucleic acids Proteins 0.000 claims 63
• 239000000523 sample Substances 0.000 claims 13
• XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 12
• 102000018511 hepcidin Human genes 0.000 claims 12
• 108060003558 hepcidin Proteins 0.000 claims 12
• 229940066919 hepcidin Drugs 0.000 claims 12
• 239000005557 antagonist Substances 0.000 claims 6
• 239000003795 chemical substances by application Substances 0.000 claims 6
• 238000000034 method Methods 0.000 claims 6
• 239000000556 agonist Substances 0.000 claims 5
• 101000716721 Homo sapiens Suprabasin Proteins 0.000 claims 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
• 102100020889 Suprabasin Human genes 0.000 claims 4
• 230000000295 complement effect Effects 0.000 claims 4
• 150000001875 compounds Chemical class 0.000 claims 4
• 238000001514 detection method Methods 0.000 claims 4
• 238000009396 hybridization Methods 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 3
• 229940079593 drug Drugs 0.000 claims 2
• 229910052742 iron Inorganic materials 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 208000019505 Deglutition disease Diseases 0.000 claims 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
• 101001021253 Homo sapiens Hepcidin Proteins 0.000 claims 1
• 206010065973 Iron Overload Diseases 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 208000007502 anemia Diseases 0.000 claims 1
• 230000003110 anti-inflammatory effect Effects 0.000 claims 1
• 230000003115 biocidal effect Effects 0.000 claims 1
• 230000008878 coupling Effects 0.000 claims 1
• 238000010168 coupling process Methods 0.000 claims 1
• 238000005859 coupling reaction Methods 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 230000008030 elimination Effects 0.000 claims 1
• 238000003379 elimination reaction Methods 0.000 claims 1
• 230000010437 erythropoiesis Effects 0.000 claims 1
• 210000000987 immune system Anatomy 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 230000000297 inotrophic effect Effects 0.000 claims 1
• 230000014759 maintenance of location Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 239000013589 supplement Substances 0.000 claims 1
• 235000019195 vitamin supplement Nutrition 0.000 claims 1